CN111514129A - Egcg在制备改善或治疗内源性内毒素血症药物或保健食品中的应用 - Google Patents
Egcg在制备改善或治疗内源性内毒素血症药物或保健食品中的应用 Download PDFInfo
- Publication number
- CN111514129A CN111514129A CN202010405675.XA CN202010405675A CN111514129A CN 111514129 A CN111514129 A CN 111514129A CN 202010405675 A CN202010405675 A CN 202010405675A CN 111514129 A CN111514129 A CN 111514129A
- Authority
- CN
- China
- Prior art keywords
- endotoxemia
- endogenous
- egcg
- improving
- fat diet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 50
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 208000037487 Endotoxemia Diseases 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 235000013402 health food Nutrition 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title description 3
- 239000002158 endotoxin Substances 0.000 claims abstract description 41
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 24
- 238000010521 absorption reaction Methods 0.000 claims abstract description 12
- 244000269722 Thea sinensis Species 0.000 claims abstract description 8
- 235000009569 green tea Nutrition 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940030275 epigallocatechin gallate Drugs 0.000 abstract description 43
- 108010004103 Chylomicrons Proteins 0.000 abstract description 25
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 5
- 210000003405 ileum Anatomy 0.000 abstract description 5
- 238000011161 development Methods 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 241000196324 Embryophyta Species 0.000 abstract 1
- 229930014626 natural product Natural products 0.000 abstract 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 22
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 6
- 239000005642 Oleic acid Substances 0.000 description 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000605059 Bacteroidetes Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 2
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 230000007358 intestinal barrier function Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及生物学及药学领域，具体公开EGCG在改善或治疗高脂饮食诱导的内源性内毒素血症的药物或保健食品中的应用。本发明首次发现绿茶中的表没食子儿茶素没食子酸酯为植物来源天然化合物，能够通过调节回肠组织中乳糜微粒的合成，进而减少内毒素的吸收，改善内源性内毒素血症。本发明为目前改善高脂饮食引起的内源性内毒素血症提供了一种全新的选择和思路，拓宽了治疗内毒素血症的选择领域，可预防和改善内毒素血症的发生和发展，为该技术领域的发展做出了贡献。
Description
技术领域
本发明涉及生物学及药学领域，具体公开EGCG在改善或治疗高脂饮食诱导的内源性内毒素血症的药物或保健食品中的应用。
背景技术
内毒素血症是一种全身性炎症反应综合征，医学上，可分为内源性内毒素血症和外源性内毒素血症，前者指肠道革兰氏阴性菌释放大量的内毒素，超过了机体清除能力从而进入血液引起；后者则指外源性感染大量内毒素，从而引发疾病。内毒素可以引起身体多个器官或组织出现功能障碍或衰竭，如肝功能受损、肾功能受损、肌肉和脂肪组织炎症水平增加、胰岛素抵抗等，严重患者甚至导致死亡，据有关文献报道，仅美国全年有3～10万病人因得不到有效治疗而死亡。
脂多糖(Lipopolysaccharide，LPS)很难从细胞壁脱落，当细菌死亡等时它会通过溶解、破坏细胞来脱落，并通过作用于细胞等而发挥其毒性。由于这种性质，它不是细菌分泌到体外的毒素(外毒素)，而是不被分泌的“存在于细菌体内的毒素”，所以又被称为内毒素。内毒素主要有以下特征，首先革兰氏阴性菌死亡后可以在肠道内持续产生LPS，产生的LPS通过TLR4依赖机制移位至肠毛细血管内，之后与食物中的脂质一同组装成为乳糜微粒，从而跨肠上皮输送到目标组织器官，最后被器官或组织细胞表面的TLR4受体识别后，触发促炎细胞因子的分泌。因此，减少LPS的分泌及其全身性输送是治疗内毒素血症的有效措施。
研究表明高脂饮食可通过增加产LPS肠道细菌的量、破坏肠屏障及促进LPS整合到乳糜微粒等引发内源性内毒素血症。厚壁菌门Firmicutes和拟杆菌门Bacteroidetes是肠道菌群的两大主要分类，其中Firmicutes呈革兰氏阳性，Bacteroidetes呈革兰氏阴性，革兰氏阴性菌的细胞壁成分之一是LPS，高脂饮食会造成F/B(Firmicutes/Bacteroidetes)的比例升高。
表没食子儿茶素没食子酸酯EGCG是绿茶的主要活性成分，约占绿茶儿茶素总量的50-60％，具有抗氧化、抗炎、抗癌抑菌等多种生物活性。现有技术有公开EGCG在制备改善肝脏验证和胰岛素抵抗药物中的应用，但肝损伤还可能由脂肪堆积、氧化应激、酒精摄入过量等很多因素引起，糖尿病也是，成病原因很多，是否由于内源性内毒素引起的并不明确。EGCG生物利用率低，大部分不被吸收，主要存在于肠道中，因此肠组织是EGCG的重要靶器官，EGCG能否通过调节肠组织中乳糜微粒的合成，改善和治疗高脂饮食诱导的内源性内毒素血症，目前尚未有相关报道。
发明内容
本发明的目的是提供一种EGCG在改善或治疗高脂饮食诱导的内源性内毒素血症的应用。
EGCG在制备改善或治疗内源性内毒素血症药物中的应用，所述的应用是将EGCG用于改善和治疗高脂饮食引起的内源性内毒素血症的药物。
所述的内源性内毒素血症由高脂饮食引起内源性内毒素的产生和吸收增加引起。
高脂饮食引起的内源性内毒素吸收增加主要经乳糜微粒运载吸收进入体内。
所述EGCG来源于绿茶。
一种EGCG在制备改善内源性内毒素血症保健食品中的应用，所述的应用是将EGCG用于改善高脂饮食引起的内源性内毒素血症的保健食品。
所述的内源性内毒素血症由高脂饮食引起内源性内毒素的产生和吸收增加引起。
高脂饮食引起的内源性内毒素吸收增加主要经乳糜微粒运载吸收进入体内。
所述EGCG来源于绿茶。
革兰氏阴性细菌细胞壁成分脂多糖(LPS)即内毒素是引起内源性内毒素血症的主要致病因子，LPS可被多个器官或组织表面的TLR4受体识别从而引发一系列炎症反应并损害其功能，高脂饮食可通过增加肠道产LPS细菌的数量、破坏肠屏障及通过合成乳糜微粒促进LPS吸收等引发内源性内毒素血症。本发明采用C57BL/6J小鼠高脂模型，通过酶联免疫法检测EGCG对高脂饮食引起的内源性内毒素血症的影响，结果表明EGCG显著降低血清LPS水平；之后检测肠道乳糜微粒合成相关基因ApoB48表达情况，发现EGCG显著降低乳糜微粒合成标志基因ApoB48的表达水平；用不同浓度EGCG处理使用Transwell培养的Caco2细胞，结果也显示EGCG可显著降低ApoB48的表达水平；实验证明，EGCG可以降低乳糜微粒的合成，减少高脂饮食中肠道LPS的吸收，这与内源性内毒素血症的改善有关。
与现有技术相比，本发明具有如下优点和有益效果：
(1)本发明为目前改善高脂饮食诱导的内源性内毒素血症的应用提供了一种全新的选择和思路，也为该技术领域的发展做出了贡献。
(2)本发明首次证实绿茶中的成分EGCG能够通过调节肠组织中乳糜微粒合成，进而改善内毒素血症。
(3)本发明提供EGCG在制备改善或治疗高脂饮食诱导的内源性内毒素血症药物中的应用和制备改善高脂饮食诱导的内源性内毒素血症保健食品中的应用，方法简单，安全无毒副作用。
附图说明
图1为实施例1所得不同组小鼠血清内毒素水平。
图2为实施例2所得不同组小鼠回肠乳糜微粒合成标志性蛋白ApoB48的表达水平。
图3为实施例3所得EGCG干预对Caco2细胞乳糜微粒合成标志性蛋白ApoB48表达水平的影响
具体实施方式
为了使本领域技术人员更好地理解本发明的技术方案能予以实施，以下结合附图和实例对本发明的具体实施作进一步说明，不应视为对本发明的范围进行限定，本发明的所有范围限定以权利要求书中的限定为准。需指出的是，以下若有未特别详细说明之过程，均是本领域技术人员可参照现有技术实现或理解的。所用试剂或仪器未注明生产厂商者，视为可以通过市售购买得到的常规产品。
实施例1实验动物分组及高脂饮食诱导的内源性内毒素模型建立
实验材料及动物：表没食子儿茶素没食子酸酯(EGCG)购自上海源叶生物科技有限公司，货号S27863，脂多糖(LPS)测定试剂盒购自北京华英生物技术研究所，实验用雄性C57BL/6J购自南开大学实验动物中心，高脂饲料D12492和低脂对照饲料D12450J均为纯化饲料，购自江苏协同医药生物工程有限责任公司。
实验方法：
(1)将30只6周龄C57BL/6小鼠置于室温为20～25℃，12h光照/12h黑暗循环的环境中适应性喂养1周后，将小鼠随机分为3组：正常饲料对照组(NC)、高脂饲料模型对照组(HFD)、EGCG干预组(HFD+EGCG)，饮水中加入EGCG，终浓度为2g/L，每7天称重1次。实验期间，所有小鼠不限制进食和饮水。每天每只小鼠大概饮水2-3mL，连续干预8周后，禁食12h，处死小鼠，收集血液、肝脏、回肠、盲肠和结肠，用预冻盐水清洗后用滤纸吸干。血液4℃过夜后，在4000rpm离心15min获得血清，置于-20℃保存，所有组织立即在液氮中冷冻，并保存在-80℃冰箱用于后期分析。
(2)血清内毒素检测：内源性内毒素LPS按照相应试剂盒说明书进行测定。
实验结果：如图1所示，高脂模型组小鼠血清LPS水平显著高于正常对照组小鼠体重(P＜0.05)，EGCG干预可显著降低内毒素LPS水平(P＜0.05)。
实施例2EGCG对乳糜微粒合成标志基因ApoB48的影响
实验材料：TRIzol购自美国Ambion公司，反转录试剂盒LunaScript SuperMix Kit和qPCR试剂盒Luna Universal qPCR Master Mix购自美国NEB公司。
实验方法：用Trizol试剂提取回肠组织中的总RNA，用Nanophotometer检测RNA的纯度，并配制1％(w/v)的琼脂糖凝胶进行检测其完整性。使用反转录试剂盒合成cDNA，将其保存于-80℃备用。
通过qPCR分析mRNA的表达水平，qPCR体系(20μL)：Luna Universal qPCR Mix 10μL、cDNA模板4μL、上游引物(10μM)0.5μL、下游引物(10μM)0.5μL、ddH2O补充至20μL。PCR反应程序为：预变性95℃ 60s，变性95℃15s，延伸60℃30s，40次循环。熔融曲线为65℃升温到95℃，持续时间5s。以β-Actin为内参基因，采用delta delta Ct法对相关基因的表达水平进行分析，引物序列如表1所示。
| 引物名称 | 上游引物(5'-3') | 下游引物(5'-3') |
| β-Actin | ACAGCAGTTGGTTGGAGCAA | ACGCGACCATCCTCCTCTTA |
| ApoB48 | TACTTCCACCCACAGTCCCCT | CCTTAGAAGCCTTGGGCACAT |
实验结果：如图2所示，高脂组小鼠回肠内乳糜微粒合成标志性蛋白ApoB48表达量显著升高，ApoB48基因表达升高代表乳糜微粒合成增加，EGCG可显著降低ApoB48的表达量，即可显著降低乳糜微粒的合成。
实施例3EGCG对Caco2细胞乳糜微粒合成的影响
实验材料：油酸购自美国sigma，货号01008
实验方法：
(1)Caco2细胞单层模型的建立与验证：用含10％胎牛血清、1％青霉素-链霉素双抗液以及1％谷氨酰胺的DMEM高糖培养基，在37℃，含5％CO2的环境下培养Caco2细胞。在悬于12孔板中的Transwell小室(0.4μm，1.12cm2)上室接种密度为1×106个/ml的Caco-2细胞悬液0.5ml，随后在下室放入1.5ml空白培养液，培养至14-21天，使之分化，从而模拟小肠上皮细胞紧密连接蛋白结构，当跨膜电阻值>600Ω时，即可认为细胞单层致密完整。
(1)用EGCG处理细胞：当Caco2细胞单层模型建立成功之后，按照前述细胞分组方式(见3.1)，并按如下方式给药。
①油酸处理组：培养基加入0.81mM的油酸；
②油酸+EGCG处理组：培养基加入0.81mM的油酸，并分别加入终浓度10、20、40μM的EGCG。
处理8h后，加入Trizol试剂吹打收集细胞，提取其RNA，进行实时荧光定量PCR实验，引物如下表2所示。
| 引物名称 | 上游引物(5'-3') | 下游引物(5'-3') |
| GAPDH | CAACGGATTTGGTCGTATTGGG | AAGGGGTCATTGATGGCAAC |
| ApoB48 | TGTCAGTACACACTGGACGC | TCAAATGCGAGGCCCATCTT |
实验结果：如图3所示，油酸可以诱导回肠内乳糜微粒的合成，加入EGCG后，乳糜微粒标志性蛋白ApoB48的表达随着EGCG浓度的增加而显著下降，从而在细胞水平上验证了EGCG可以降低乳糜微粒的合成。
LPS可与食物中的脂质一起进入肠上皮细胞，形成乳糜微粒，从而被吸收进入血液，乳糜微粒的减少，有助于减少脂质和LPS的吸收。
由以上实施例可以看出EGCG具有改善和治疗内源性内毒素血症的功能，因此按照药品或保健食品的制备方法制备含有EGCG的药品可以改善或治疗内源性内毒素血症。
以上实施例仅为本发明较优的实施方式，仅用于解释本发明，而非限制本发明，本领域技术人员在未脱离本发明精神实质下所作的改变、替换、修饰等均应属于本发明的保护范围。
Claims (8)
1.EGCG在制备改善或治疗内源性内毒素血症药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述的内源性内毒素血症由高脂饮食引起内源性内毒素的产生和吸收增加引起。
3.根据权利要求2所述的应用，其特征在于，高脂饮食引起的内源性内毒素吸收增加主要经乳糜微粒运载吸收进入体内。
4.根据权利要求1所述的应用，其特征在于，所述EGCG来源于绿茶。
5.EGCG在制备改善内源性内毒素血症保健食品中的应用。
6.根据权利要求5所述的应用，其特征在于，所述的内源性内毒素血症由高脂饮食引起内源性内毒素的产生和吸收增加引起。
7.根据权利要求6所述的应用，其特征在于，高脂饮食引起的内源性内毒素吸收增加主要经乳糜微粒运载吸收进入体内。
8.根据权利要求5所述的应用，其特征在于，所述EGCG来源于绿茶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010405675.XA CN111514129A (zh) | 2020-05-14 | 2020-05-14 | Egcg在制备改善或治疗内源性内毒素血症药物或保健食品中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010405675.XA CN111514129A (zh) | 2020-05-14 | 2020-05-14 | Egcg在制备改善或治疗内源性内毒素血症药物或保健食品中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111514129A true CN111514129A (zh) | 2020-08-11 |
Family
ID=71907868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010405675.XA Pending CN111514129A (zh) | 2020-05-14 | 2020-05-14 | Egcg在制备改善或治疗内源性内毒素血症药物或保健食品中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111514129A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470152A (zh) * | 2009-07-30 | 2012-05-23 | 丹尼斯科公司 | 用于治疗内毒素血症的乳酸菌和双歧杆菌 |
| CN105497010A (zh) * | 2015-12-16 | 2016-04-20 | 孙荣距 | Egcg在制备对抗脓毒症细菌内毒素靶向药物中的应用 |
| US20170246235A1 (en) * | 2014-09-03 | 2017-08-31 | Plandai Biotechnology Inc. | Green tea compositions |
-
2020
- 2020-05-14 CN CN202010405675.XA patent/CN111514129A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102470152A (zh) * | 2009-07-30 | 2012-05-23 | 丹尼斯科公司 | 用于治疗内毒素血症的乳酸菌和双歧杆菌 |
| US20170246235A1 (en) * | 2014-09-03 | 2017-08-31 | Plandai Biotechnology Inc. | Green tea compositions |
| CN105497010A (zh) * | 2015-12-16 | 2016-04-20 | 孙荣距 | Egcg在制备对抗脓毒症细菌内毒素靶向药物中的应用 |
Non-Patent Citations (6)
| Title |
|---|
| GENEVIE`VE PILON 等: "Endotoxin Mediated-iNOS Induction Causes Insulin Resistance via ONOO2 Induced Tyrosine Nitration of IRS-1 in Skeletal Muscle", 《PLOS ONE》 * |
| KATHERINE GIL-CARDOSO 等: "The co-administration of proanthocyanidins and an obesogenic diet prevents the increase in intestinal permeability and metabolic endotoxemia derived to the diet", 《JOURNAL OF NUTRITIONAL BIOCHEMISTRY》 * |
| 李木子 等: "TLR4/Myd88/NF/kB通路介导表没食子儿茶素没食子酸酯对脓毒血症大鼠急性肾损伤的保护作用", 《中国医科大学学报》 * |
| 李永渝 等: "《临床消化病理生理学》", 31 October 1995, 贵州科技出版社 * |
| 白娟: "苦瓜干预肥胖大鼠内毒素血症与肠道菌群的相关性及机制", 《中国博士学位论文全文数据库 工程科技I辑》 * |
| 莫国贤 等: "《保胆外科学》", 31 January 2017, 科学技术文献出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | L-tryptophan enhances intestinal integrity in diquat-challenged piglets associated with improvement of redox status and mitochondrial function | |
| Kim et al. | Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice | |
| Dai et al. | Sodium butyrate ameliorates high-concentrate diet-induced inflammation in the rumen epithelium of dairy goats | |
| Frasca et al. | Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells | |
| Nassar et al. | Immunostimulant effect of Egyptian propolis in rabbits | |
| Li et al. | Pogostone suppresses proinflammatory mediator production and protects against endotoxic shock in mice | |
| CN113616644B (zh) | Rna解旋酶dhx33抑制剂在制备用于治疗白血病的药物中的应用 | |
| CN108348543A (zh) | 促进肝再生的方法 | |
| KR102402139B1 (ko) | 낭창성 신염을 치료하기 위한 진세노사이드 m1의 용도 | |
| Camps-Bossacoma et al. | Cocoa diet and antibody immune response in preclinical studies | |
| Miao et al. | Baicalin attenuates endometritis in a rabbit model induced by infection with Escherichia coli and Staphylococcus aureus via NF-κB and JNK signaling pathways | |
| Mahapatra et al. | Immunomodulatory Role of Ocimum gratissimum and Ascorbic Acid against Nicotine‐Induced Murine Peritoneal Macrophages In Vitro | |
| CN113424795B (zh) | 一种急性胰腺炎动物模型的构建方法和用途 | |
| CN111514129A (zh) | Egcg在制备改善或治疗内源性内毒素血症药物或保健食品中的应用 | |
| Safitri et al. | Effectiveness of forest honey (Apis dorsata) as therapy for ovarian failure causing malnutrition | |
| Zhu et al. | FTY720 inhibits the development of collagen-induced arthritis in mice by suppressing the recruitment of CD4+ T lymphocytes | |
| Xu et al. | Resveratrol attenuates IL‑33‑induced mast cell inflammation associated with inhibition of NF‑κB activation and the P38 signaling pathway | |
| CN114569721B (zh) | 载药的胞外囊泡在制备治疗肥胖或减轻肥胖相关代谢指标的药物中的应用 | |
| Kim et al. | Application of milk exosomes for musculoskeletal health: talking points in recent outcomes | |
| Chen et al. | Hibiscus manihot L improves obesity in mice induced by a high-fat diet | |
| CN107007610B (zh) | 二苯甲酮类化合物在制药中的应用 | |
| CN116987612B (zh) | 一种耐盐芽孢杆菌sw207及其应用 | |
| WO2015017336A1 (en) | Combination and method for administration to an animal | |
| US11998541B2 (en) | Method for alleviating chronic liver disease using Rosoxacin | |
| US20230338398A1 (en) | Use of delta-8-thc to treat inflammatory and autoimmune diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200811 |